When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

Researchers discover that bone marrow cancer cells diversify drastically when exiting the bone marrow, which also affects the ...

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

A research team from the Heidelberg Medical Faculty, the German Cancer Research Center (DKFZ), the Berlin Institute of Health ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients.

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...

Researchers sought to determine whether teclistamab would lead to a clinical response in patients with relapsed/refractory multiple myeloma.

One of the biggest risk is probably aging, myeloma is more common as people grow older. So the median age at which patients get diagnosed with myeloma is about 68/69 years. So it's still predominantly ...